Ингаляция комбинированного препарата 7%-го гипертонического раствора хлорида натрия и 0,1%-ной гиалуроновой кислоты в составе комплексной терапии больных муковисцидозом: результаты российского наблюдательного исследования

This was an observational prospective cohort study of safety and efficacy of mucolytic therapy with i nhaled combination of 7% hypertonic saline (HS) and 0.1% hyaluronic acid (HA) in patients with cystic fibrosis (CF). The treatment duration was 4 weeks, the follow-up of patients was continued up to 8 weeks. Methods. The study involved 74 CF patients aged > 12 years. A comparative analysis of respiratory function, patients’ satisfaction with therapy, and efficacy and safety of 4-wk treatment was performed in groups of patients treated with 7% HS (n = 33) or HA (n = 41). Changes in patients’ status (n = 41) were assessed after 8 weeks. Results. The forced expiratory volume for 1 sec (FEV1) increased by 5.8% (p = 0.037) after 4-wk therapy with HA and additionally increased by 5.5% (p = 0.020) in 8 weeks after starting the treatment; the total growth in FEV1 during the study was 11.3% (p < 0.001). FEV1 did not improve in the HS group. Nasal and ear congestion, mucus in the throat or in the chest ( 62.9% vs 83.9%; p = 0.0014), appearance or worsening of cough (68.8% vs 93.8%; p < 0.0001), sore throat (43.8% vs 68.8%; p = 0.0006); unpleasant taste (29.4% vs 43.8%; p = 0.0398), and balance disorder (12.5% vs 3.1%; p = 0.0317) significantly differed between the groups. Conclusion. HA was better tolerated compared to HS in CF patients. One-month therapy with HA could decrease frequency and severity of sore throat, cough and nasal congestion in CF patients. Prolonged treatment with HA for 2 months was associated with improved tolerability of the drug and significant increase in FEV1.